A biomarker-based definition of AD was established by the National Institute on Aging and Alzheimer’s Association using the amyloid–tau–neurodegeneration framework, reflecting clinicopathological correlation and enabling earlier biologically grounded diagnosis [3,4]. This evidence concerns the gene MAPT and Alzheimer disease.